AMGN
Amgen·NASDAQ
--
--(--)
--
--(--)
AMGN fundamentals
Amgen (AMGN) released its earnings on Feb 3, 2026: revenue was 9.87B (YoY +8.63%), beat estimates; EPS was 5.29 (YoY -0.38%), beat estimates.
Revenue / YoY
9.87B
+8.63%
EPS / YoY
5.29
-0.38%
Report date
Feb 3, 2026
AMGN Earnings Call Summary for Q4,2025
- Revenue Growth: 10% full-year growth, driven by Repatha (36%), EVENITY (34%), and rare disease portfolio ($5.2B).
- Pipeline Breakthroughs: MariTide Phase III expansion, Repatha's VESALIUS-CV cardiovascular data, and UPLIZNA's gMG approval.
- Financial Strength: $8.1B free cash flow, 2026 guidance for $30.8B-$31.8B revenue, and $21.60-$23.00 EPS.
- Strategic Initiatives: MariTide launch preparation, AmgenNow program, and biosimilar expansion.
EPS
Actual | 4.17 | 4.25 | 4.37 | 3.81 | 3.7 | 4.38 | 4.67 | 4.36 | 4.25 | 4.65 | 4.7 | 4.09 | 3.98 | 5 | 4.96 | 4.71 | 3.96 | 4.97 | 5.58 | 5.31 | 4.9 | 6.02 | 5.64 | 5.29 | ||||||||||||||||
Forecast | 3.7399 | 3.8221 | 3.9263 | 3.3553 | 4.0479 | 4.0885 | 4.2949 | 4.0356 | 4.0953 | 4.4326 | 4.4667 | 4.0968 | 3.8473 | 4.4926 | 4.6691 | 4.5914 | 3.879 | 4.9847 | 5.2744 | 5.0906 | 4.2697 | 5.2814 | 5.019 | 4.7344 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +11.50% | +11.20% | +11.30% | +13.55% | -8.59% | +7.13% | +8.73% | +8.04% | +3.78% | +4.90% | +5.22% | -0.17% | +3.45% | +11.29% | +6.23% | +2.58% | +2.09% | -0.29% | +5.79% | +4.31% | +14.76% | +13.98% | +12.37% | +11.74% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.16B | 6.21B | 6.42B | 6.63B | 5.90B | 6.53B | 6.71B | 6.85B | 6.24B | 6.59B | 6.65B | 6.84B | 6.11B | 6.99B | 6.90B | 8.20B | 7.45B | 8.39B | 8.50B | 9.09B | 8.15B | 9.18B | 9.56B | 9.87B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.00B | 6.19B | 6.39B | 6.57B | 6.26B | 6.46B | 6.67B | 6.87B | 6.07B | 6.53B | 6.56B | 6.74B | 6.15B | 6.66B | 6.93B | 8.13B | 7.45B | 8.35B | 8.50B | 8.88B | 8.06B | 8.94B | 8.97B | 9.47B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +2.70% | +0.18% | +0.55% | +0.92% | -5.76% | +1.06% | +0.57% | -0.34% | +2.78% | +0.96% | +1.34% | +1.41% | -0.80% | +4.84% | -0.33% | +0.86% | -0.06% | +0.43% | +0.06% | +2.31% | +1.14% | +2.72% | +6.59% | +4.18% |
Earnings Call
You can ask Aime
What factors drove the changes in Amgen's revenue and profit?Did Amgen beat or miss consensus estimates last quarter?What guidance did Amgen's management provide for the next earnings period?What is the market's earnings forecast for Amgen next quarter?What is the revenue and EPS growth rate for Amgen year over year?What is Amgen's gross profit margin?What is Amgen's latest dividend and current dividend yield?What were the key takeaways from Amgen’s earnings call?
